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Background
This study was undertaken to determine whether use of the direct renin inhibitor 
aliskiren would reduce cardiovascular and renal events in patients with type 2 dia-
betes and chronic kidney disease, cardiovascular disease, or both.
Methods
In a double-blind fashion, we randomly assigned 8561 patients to aliskiren (300 mg 
daily) or placebo as an adjunct to an angiotensin-converting–enzyme inhibitor or an 
angiotensin-receptor blocker. The primary end point was a composite of the time 
to cardiovascular death or a first occurrence of cardiac arrest with resuscitation; 
nonfatal myocardial infarction; nonfatal stroke; unplanned hospitalization for 
heart failure; end-stage renal disease, death attributable to kidney failure, or the 
need for renal-replacement therapy with no dialysis or transplantation available or 
initiated; or doubling of the baseline serum creatinine level.
Results
The trial was stopped prematurely after the second interim efficacy analysis. After 
a median follow-up of 32.9 months, the primary end point had occurred in 783 
patients (18.3%) assigned to aliskiren as compared with 732 (17.1%) assigned to 
placebo (hazard ratio, 1.08; 95% confidence interval [CI], 0.98 to 1.20; P = 0.12). 
Effects on secondary renal end points were similar. Systolic and diastolic blood pres-
sures were lower with aliskiren (between-group differences, 1.3 and 0.6 mm Hg, 
respectively) and the mean reduction in the urinary albumin-to-creatinine ratio was 
greater (between-group difference, 14 percentage points; 95% CI, 11 to 17). The 
proportion of patients with hyperkalemia (serum potassium level, ≥6 mmol per liter) 
was significantly higher in the aliskiren group than in the placebo group (11.2% vs. 
7.2%), as was the proportion with reported hypotension (12.1% vs. 8.3%) (P<0.001 
for both comparisons).
Conclusions
The addition of aliskiren to standard therapy with renin–angiotensin system block-
ade in patients with type 2 diabetes who are at high risk for cardiovascular and 
renal events is not supported by these data and may even be harmful. (Funded by 
Novartis; ALTITUDE ClinicalTrials.gov number, NCT00549757.)
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Mortality associated with type 2 diabetes remains nearly twice that when diabetes is absent.1 Complications of dia-
betes, particularly renal and cardiovascular disease, 
substantially increase the risk of subsequent se-
vere illness and death. When a patient has both 
renal and cardiovascular disease, the risk is mag-
nified further.2,3 Blood-pressure lowering is benefi-
cial in slowing renal-disease progression, reducing 
cardiovascular disease events, and preventing pre-
mature death.4 Renin–angiotensin–aldosterone 
system (RAAS) blockers are highly effective, with 
apparent benefits extending beyond simple blood-
pressure lowering5-8; such agents have become the 
preferred first-line interventions in high-risk per-
sons with diabetes.
Theoretically, dual RAAS blockade should be 
more effective than a single agent, yet the results 
of both the Valsartan in Acute Myocardial Infarc-
tion Trial and the Ongoing Telmisartan Alone 
and in Combination with Ramipril Global End-
point Trial did not support combined therapy with 
an angiotensin-converting–enzyme (ACE) inhibi-
tor and an angiotensin-receptor blocker (ARB).9,10 
The lack of benefit could be due to the deleterious 
effects of aldosterone escape and compensatory 
renin activation.11-13 Aliskiren is a renin inhibitor 
that reduces plasma renin activity, and aliskiren 
combined with an ARB, as compared with an ARB 
alone, has been shown to result in a greater de-
crease in albuminuria in diabetic renal disease.14 
The effect of dual therapy on hard renal outcomes 
(e.g., end-stage renal disease and death from kid-
ney failure) and on cardiovascular disease itself is 
unknown.
The present trial was designed to determine the 
effectiveness and safety of direct renin inhibition 
with aliskiren, as compared with placebo, with 
respect to fatal and nonfatal renal and cardio-
vascular events in patients with type 2 diabetes 
who were at high risk for these complications 
and were already taking an ACE inhibitor or an 
ARB per standard practice. Thus, our trial was 
designed to evaluate the safety of dual RAAS 
blockade.
Me thods
Study Design
The Aliskiren Trial in Type 2 Diabetes Using Car-
diorenal Endpoints (ALTITUDE) was a random-
ized, double-blind, placebo-controlled trial con-
ducted at 853 centers in 36 countries. Details of 
the trial design and methods have been published 
previously,15 and the protocol and its amendments 
are available with the full text of this article at 
NEJM.org. The trial was approved by the ethics 
committee or institutional review board at each 
participating center. All patients provided written 
informed consent. We enrolled men and women 
35 years of age or older with type 2 diabetes and 
evidence of microalbuminuria, macroalbuminuria, 
or cardiovascular disease, as described in Table 
S1 in the Supplementary Appendix, available at 
NEJM.org.
The primary outcome was a composite of death 
from cardiovascular causes or the first occurrence 
of cardiac arrest with resuscitation; nonfatal myo-
cardial infarction; nonfatal stroke; unplanned 
hospitalization for heart failure; end-stage renal 
disease, death attributable to kidney failure, or 
the need for renal-replacement therapy with no 
dialysis or transplantation available or initiated; or 
a serum creatinine value that was at least double 
the baseline value and that exceeded the upper 
limit of the normal range (>80 μmol per liter 
[0.9 mg per deciliter] in women and >106 μmol 
per liter [1.2 mg per deciliter] in men), sustained 
for at least a month.15 The secondary cardiovas-
cular outcome was a composite of all five cardio-
vascular components of the primary composite 
end point. Similarly, the secondary renal outcome 
was a composite of the renal components of the 
primary composite end point. Confirmatory data 
for all potential study end points were collected 
from the study investigators and adjudicated by 
a central adjudication committee at Brigham and 
Women’s Hospital, whose members were not 
aware of the study-group assignments. End points 
were adjudicated according to standard criteria, 
as described previously15 (Table S2 in the Supple-
mentary Appendix).
The executive committee designed the trial and 
wrote the study protocol in collaboration with 
coauthors who are employees of Novartis. The first 
author drafted the report with contributions from 
all authors, who also reviewed and approved the 
manuscript. All authors jointly decided to submit 
the manuscript for publication, and all authors 
vouch for the accuracy of the data and the fidel-
ity of the study to the protocol. The sponsor 
(Novartis) collected and managed the data with 
oversight by the executive committee. Indepen-
dent statisticians at Axio Research prepared the 
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interim unblinded reports for the independent data 
and safety monitoring committee, which oversaw 
patient safety and the quality of trial conduct. 
The full data set was transferred to Brigham and 
Women’s Hospital at study completion. The statis-
tical analysis was performed by the sponsor and 
verified by the independent group at Brigham and 
Women’s Hospital. 
Run-in Period, Randomization, and Follow-up
Eligible patients entered a 4-to-12-week screen-
ing period and were subsequently randomly as-
signed to receive aliskiren or placebo in addition 
to standard treatment and were followed for a 
median of 32.9 months, as described in detail in 
the Methods section in the Supplementary Appen-
dix. The initial dose of aliskiren, 150 mg once daily, 
was increased to 300 mg once daily at 4 weeks 
after randomization if there were no safety con-
cerns. The investigators adhered to clinical-prac-
tice guidelines for hyperkalemia management 
(Table S3 in the Supplementary Appendix).
Interim Analyses and Data Monitoring
An independent data and safety monitoring com-
mittee (see the Acknowledgments section in the 
Supplementary Appendix) met twice yearly; two 
formal interim analyses were conducted when 
approximately one third and two thirds of the 
total primary composite events had occurred. At 
the second interim efficacy analysis and the sev-
enth interim safety analysis (December 14, 2011), 
the independent data and safety monitoring com-
mittee recommended termination of the study 
medication, on the basis of their assessment that 
the excess risk of adverse events in the aliskiren 
group could not be offset by a reduction in major 
cardiovascular and renal events (Table S4 and let-
ter from the data and safety monitoring commit-
tee in the Supplementary Appendix). A futility 
analysis was neither planned for the trial nor in-
cluded in the charter of the data and safety mon-
itoring committee. However, the statistician on 
the committee performed a futility analysis and 
calculated the conditional power. The supply of 
study medication was stopped immediately, and 
all investigators were instructed to stop trial 
medication in each patient no later than January 
6, 2012. All end points occurring before or on 
January 31, 2012, are noted in this report. After 
trial termination, patients were asked to return 
for a safety-assessment visit and were invited to 
participate in a yearlong safety-extension study 
(without the use of the study drugs).
Statistical Analysis
The trial was designed to enroll 8600 patients 
and to continue until 1620 patients reached the 
primary composite end point, with the assump-
tion of an annual event rate of 8% in the placebo 
group, in order to provide 90% power to detect a 
reduction in risk of 15% or more at a significance 
level of 5%. The sample size was adjusted to in-
clude an assumed 8% total dropout rate, with two 
equally spaced interim analyses based on the Lan–
DeMets alpha spending function approximating 
the O’Brien–Fleming boundaries.
The main analysis used the time-to-first-event 
approach, based on the Cox proportional-hazards 
model stratified according to history of cardio-
vascular disease (yes or no) and baseline urinary 
albumin-to-creatinine ratio (with albumin mea-
sured in milligrams and creatinine measured in 
grams) of 200 or higher (yes or no), as prespeci-
fied in the protocol. Confidence intervals, hazard 
ratios, and nominal P values were obtained on 
the basis of the above model. All primary out-
come analyses were confirmed by an independent 
statistician at Brigham and Women’s Hospital. 
All reported P values are two-sided and have not 
been adjusted for multiple comparisons. Holm’s 
multiple-comparison procedure was used for the 
comparisons of secondary end points. Estimates 
of cumulative event rates are shown as Kaplan–
Meier curves. All comparisons were based on the 
intention-to-treat principle (with data from the full 
analysis set). The consistency of the study-drug 
effect in prespecified subgroups was assessed with 
the use of the same Cox model, with an addi-
tional test for the interaction between study drug 
and each subgroup covariate.
For the principal analysis of the primary and 
secondary composite end points, 0.046 was es-
tablished as the threshold for statistical signifi-
cance after accounting for the two interim effi-
cacy analyses (performed when 35% and 69% of 
the events had occurred). For other analyses, 0.05 
was considered to indicate statistical significance. 
Assessments of safety were based on data from 
the patients who received at least one dose of the 
study drug. A repeated-measure analysis of covari-
ance was used to assess the overall difference in 
mean systolic blood pressure and mean diastolic 
blood pressure between the study groups.
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R esult s
Study Population
Of 21,157 patients screened at 838 centers in 36 
countries, 8606 (40.7%) were randomly assigned 
to aliskiren or placebo between October 10, 2007, 
and June 23, 2010. After randomization, 45 par-
ticipants were excluded from the analysis (22 un-
derwent randomization by mistake, and 23 were 
excluded because of violations in Good Clinical 
Practice guidelines at two sites, resulting in the 
closure of both sites), leaving a study population 
of 8561 patients who could be evaluated (Fig. S1 
in the Supplementary Appendix).
Baseline characteristics were similar in the 
aliskiren and placebo groups (Table 1, and Table 
S5 in the Supplementary Appendix). Eighty-two 
percent of patients in each group had had diabe-
tes for at least 5 years, and 8086 patients (94.5%) 
had received a diagnosis of hypertension. Overall, 
3619 patients (42.3%) had known cardiovascular 
diseases other than hypertension, mainly coronary 
artery disease. Nearly all patients had chronic 
kidney disease (98.0%), and 84.1% had protein-
uria. A total of 40.8% of patients had a baseline 
systolic blood pressure higher than 140 mm Hg, 
and 12.2% had a diastolic blood pressure higher 
than 85 mm Hg. Participants with cardiovascu-
lar disease were receiving more intensive treat-
ment at baseline than those without such disease 
— 71.2% were taking diuretics (vs. 57.3% of 
those without cardiovascular disease), 80.5% were 
receiving antiplatelet agents (vs. 48.1%), 69.5% 
were taking beta-blockers (vs. 35.9%), and 79.6% 
were taking statins (vs. 54.6%). An exception was 
that fewer patients with cardiovascular disease 
were taking calcium-channel blockers (55.7% vs. 
65.5%). A total of 56.7% of all patients were tak-
ing insulin. Medications at baseline are shown in 
Table S6 in the Supplementary Appendix. During 
the trial, the use of most concomitant antihyper-
tensive drugs remained nearly unchanged (Table 
S7 in the Supplementary Appendix), as did the 
dose of the most commonly used ACE inhibitors 
and ARBs (data not shown).
At 2 months after randomization, 84.1% of 
patients in the aliskiren group were taking the 
higher dose (300 mg daily), and 86.3% of patients 
in the placebo group were taking the study medi-
cation (P = 0.006). At 1 year, 84.6% of surviving 
participants assigned to aliskiren were taking the 
study medication, as compared with 87.3% of 
those assigned to placebo (P<0.001). At 2 years, 
these percentages were 74.1% and 78.7% (P<0.001), 
respectively, and at 3 years, 65.7% and 70.1% 
(P = 0.009).
Study Follow-up
A total of 123 patients in the aliskiren group 
(2.9%) and 99 in the placebo group (2.3%) were 
lost to follow-up (including withdrawal of con-
sent) (Fig. S1 in the Supplementary Appendix); 
information on vital status was available for 
98.3% of the maximum possible follow-up time 
in both study groups. The median follow-up pe-
riods for vital status for the primary cardiorenal 
Table 1. Baseline Characteristics of the Patients.*
Characteristic
Aliskiren 
(N = 4274)
Placebo 
(N = 4287)
Age — yr 64.6±9.6 64.4±9.9
Female sex — no. (%) 1393 (32.6) 1342 (31.3)
Current smoker — no. (%) 557 (13.0) 571 (13.3)
Body-mass index† 29.9±5.8 29.9±5.9
Blood pressure in the sitting position — mm Hg
Systolic 137.3±16.2 137.3±16.7
Diastolic 74.1±9.8 74.3±9.9
Glycated hemoglobin — % 7.8±1.6 7.8±1.6
Estimated GFR‡
Mean — ml/min/1.73 m2 57.0±21.9 57.0±23.0
Category — no. (%)
<30 ml/min/1.73 m2 92 (2.2) 118 (2.8)
≥30 to <45 ml/min/1.73 m2 1244 (29.1) 1294 (30.2)
≥45 to <60 ml/min/1.73 m2 1534 (35.9) 1494 (34.8)
≥60 ml/min/1.73 m2 1402 (32.8) 1381 (32.2)
Missing data 2 (<0.1) 0
Urinary albumin-to-creatinine ratio
Geometric mean — mg/g 206 208
Interquartile range — mg/g 57–866 58–912
Category — no. (%)
<20 mg/g 614 (14.4) 620 (14.5)
≥20 to <200 mg/g 1105 (25.9) 1089 (25.4)
≥200 mg/g 2486 (58.2) 2517 (58.7)
Missing data 69 (1.6) 61 (1.4)
* Plus–minus values are means ±SD unless otherwise noted. There were no sig-
nificant differences (at P<0.05) between the two groups for any of the variables 
listed.
† The body-mass index is the weight in kilograms divided by the square of the 
height in meters.
‡ The estimated glomerular filtration rate (GFR) was calculated with the use of 
the modified Modification of Diet in Renal Disease formula for isotope dilution 
mass spectrometry–traceable serum creatinine values.16
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composite outcome, the cardiovascular composite 
outcome, and the renal composite outcome were 
2.8, 2.8, and 2.7 years, respectively.
Primary Cardiorenal Composite Outcome
The primary outcome occurred in 783 participants 
in the aliskiren group (18.3%) and 732 in the pla-
cebo group (17.1%) (Table 2 and Fig. 1A). The haz-
ard ratio for this outcome in the aliskiren group as 
compared with the placebo group was 1.08 (95% 
confidence interval [CI], 0.98 to 1.20; P = 0.12). 
The study-drug effect was consistent across all 
prespecified subgroups except for baseline serum 
potassium concentration and status with respect 
to biguanide use (Fig. S2 in the Supplementary 
Appendix). Patients with a baseline potassium 
level of 5.0 mmol per liter or higher had a greater 
risk of the primary composite outcome with 
aliskiren than with placebo, as compared with pa-
tients with a potassium level below 5.0 mmol per 
liter (Table S8 in the Supplementary Appendix).
Secondary Cardiovascular Composite 
Outcome
The secondary cardiovascular composite outcome 
occurred in 590 participants in the aliskiren group 
(13.8%) and 539 in the placebo group (12.6%); the 
hazard ratio in the aliskiren group was 1.11 (95% 
CI, 0.99 to 1.25; P = 0.09) (Table 2 and Fig. 1B). 
All components of the cardiovascular outcome, 
with the exception of unplanned hospitalization for 
heart failure, occurred more frequently in the 
aliskiren group, and the excess of patients who 
had cardiac arrest with resuscitation (19 in the 
aliskiren group vs. 8 in the placebo group) was 
nominally significant (Table 2).
Secondary Renal Composite Outcome
The secondary renal composite outcome occurred 
in 257 participants in the aliskiren group (6.0%) 
and 251 in the placebo group (5.9%); the hazard 
ratio in the aliskiren group was 1.03 (95% CI, 0.87 
to 1.23; P = 0.74) (Table 2 and Fig. 1C). There were 
no significant differences between study groups for 
any component of the renal outcome (Table 2).
Deaths
The number of deaths from any cause did not dif-
fer significantly between the study groups (Table 
2). The number of adjudicated deaths that were 
sudden (or presumed to be sudden) was 119 in 
the aliskiren group and 102 in the placebo group.
Changes in Blood Pressure and Kidney 
Function
Blood pressure increased during follow-up, but 
the overall increase was smaller with aliskiren 
than with placebo (between-group differences, 
Table 2. Prespecified Primary and Secondary Composite Outcomes and Deaths.*
Outcome
Aliskiren 
(N = 4274)
Placebo 
(N = 4287)
Hazard Ratio 
(95% CI) P Value†
no. of patients (%)
Primary composite outcome 783 (18.3) 732 (17.1) 1.08 (0.98–1.20) 0.12
Death from cardiovascular causes 246 (5.8) 215 (5.0) 1.16 (0.96–1.39) 0.12
Cardiac arrest with resuscitation 19 (0.4) 8 (0.2) 2.40 (1.05–5.48) 0.04
Myocardial infarction (fatal or nonfatal) 147 (3.4) 142 (3.3) 1.04 (0.83–1.31) 0.72
Stroke (fatal or nonfatal) 147 (3.4) 122 (2.8) 1.22 (0.96–1.55) 0.11
Unplanned hospitalization for heart failure 205 (4.8) 219 (5.1) 0.95 (0.78–1.14) 0.56
ESRD, death attributable to kidney failure, 
or loss of kidney function‡
121 (2.8) 113 (2.6) 1.08 (0.84–1.40) 0.56
Doubling of baseline serum creatinine 210 (4.9) 217 (5.1) 0.97 (0.80–1.17) 0.75
Cardiovascular composite outcome 590 (13.8) 539 (12.6) 1.11 (0.99–1.25) 0.09
Renal composite outcome 257 (6.0) 251 (5.9) 1.03 (0.87–1.23) 0.74
Death from any cause 376 (8.8) 358 (8.4) 1.06 (0.92–1.23) 0.42
* A patient may have had multiple cardiovascular and renal events of different types. All composite outcomes reflect only 
the first occurrence of any of the components.
† P values have not been adjusted for multiple comparisons.
‡ Loss of kidney function was defined by the need for renal-replacement therapy with no dialysis or transplantation available 
or initiated. ESRD denotes end-stage renal disease.
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(1.3 mm Hg systolic and 0.6 mm Hg diastolic) (Fig. 
S3 in the Supplementary Appendix). The adjusted 
least-squares mean increase in systolic pressure be-
tween baseline and 6 months was 1.5 mm Hg (95% 
CI, 1.0 to 2.0) with aliskiren versus 3.4 mm Hg 
(95% CI, 2.9 to 3.9) with placebo, for a difference 
of 1.9 mm Hg (95% CI, 1.2 to 2.6; P<0.001). The 
change in diastolic pressure was −0.2 mm Hg 
(95% CI, −0.5 to 0.0) versus 0.7 mm Hg (95% CI, 
0.5 to 1.0), for a difference of 1.0 mm Hg (95% 
CI, 0.6 to 1.4; P<0.001).
The overall urinary albumin-to-creatinine ra-
tio decreased more with aliskiren than with pla-
cebo (between-group difference, 14 percentage 
points; 95% CI, 11 to 17) (Fig. S3 in the Supple-
mentary Appendix). The decrease between base-
line and 6 months was 16% (95% CI, 13 to 18) 
with aliskiren versus 5% (95% CI, 3 to 8) with 
placebo, for a difference of 11 percentage points 
(95% CI, 7 to 15; P<0.001).
The adjusted least-squares mean decrease in 
the estimated glomerular filtration rate (GFR) 
between baseline and 6 months was 2.45 ml per 
minute per 1.73 m2 of body-surface area (95% CI, 
2.11 to 2.78) with aliskiren versus 1.29 ml per 
minute per 1.73 m2 (95% CI, 0.95 to 1.62) with 
placebo, for a difference of 1.16 ml per minute per 
1.73 m2 (95% CI, 0.69 to 1.63; P<0.001) (Fig. S3 
in the Supplementary Appendix).
Adverse Events and Discontinuation  
of the Study Drug
During the trial, 1445 patients assigned to aliski-
ren (33.8%) and 1218 assigned to placebo (28.4%) 
discontinued the study drug permanently for a 
reason other than death (P = 0.001). In the aliski-
ren group, 563 patients (13.2%) discontinued the 
study drug because of an adverse event, as com-
pared with 437 patients (10.2%) in the placebo 
group (P<0.001).
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Figure 1. Kaplan–Meier Curves for the Primary 
Composite Outcome, Secondary Cardiovascular  
Composite Outcome, and Secondary Renal Composite 
Outcome.
The primary composite outcome was the time to cardio-
vascular death or the first occurrence of cardiac arrest 
with resuscitation, nonfatal myocardial infarction, non-
fatal stroke, unplanned hospitalization for heart failure, 
end-stage renal disease or death from renal causes, or a 
doubling of the baseline serum creatinine concentration 
that was sustained for at least a month (Panel A). The 
secondary cardiovascular outcome was a composite of 
all five cardiovascular elements in the primary compos-
ite end point (Panel B). Similarly, the secondary renal 
outcome was a composite of the renal elements in the 
primary composite end point (Panel C).
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Hyperkalemia was the most common adverse 
event reported by investigators and the most com-
mon adverse event leading to discontinuation of 
the study drug (Table 3). Serum potassium was 
also measured at regular intervals during the trial. 
The number of patients with a maximum uncon-
firmed postbaseline potassium level of 5.5 to less 
than 6.0 mmol per liter was 907 in the aliskiren 
group (21.2%) and 723 in the placebo group 
(16.9%); for a potassium level of 6.0 mmol per 
liter or higher, these figures were 479 (11.2%) 
and 308 (7.2%), respectively (P<0.001 for both 
comparisons). The frequency of a maximum se-
rum potassium level above 5.0 mmol per liter 
during the study was 15% higher among pa-
tients with a baseline estimated GFR below 
45 ml per minute per 1.73 m2 than among those 
with a higher estimated GFR.
As expected, renal impairment and hypotension 
were more commonly reported in the aliskiren 
group than in the placebo group; they were the 
second and third most common adverse events 
leading to study-drug discontinuation (Table 3). 
The next most commonly recorded cause of 
study-drug discontinuation was stroke (in 25 
patients in the aliskiren group and 18 in the 
placebo group). Reported hypotension was more 
frequent in elderly patients (>65 years of age), 
those with a pulse pressure below the median 
(68 mm Hg), and those receiving treatment with 
loop diuretics at baseline (data not shown). Re-
ported hypoglycemia was slightly more frequent 
Table 3. Most Commonly Reported Adverse Events and Study-Drug Discontinuation.*
Event Any Event Reported P Value
Event Leading to Permanent 
Study-Drug Discontinuation P Value
Aliskiren 
(N = 4272)
Placebo 
(N = 4285)
Aliskiren 
(N = 4272)
Placebo 
(N = 4285)
no. of patients (%) no. of patients (%)
Hyperkalemia 1670 (39.1) 1244 (29.0) <0.001 205 (4.8) 111 (2.6) <0.001
Peripheral edema 686 (16.1) 706 (16.5) 0.60 11 (0.3) 7 (0.2) 0.34
Hypotension 519 (12.1) 357 (8.3) <0.001 28 (0.7) 13 (0.3) 0.02
Diarrhea 417 (9.8) 312 (7.3) <0.001 11 (0.3) 7 (0.2) 0.34
Hypertension 429 (10.0) 469 (10.9) 0.17 3 (0.1) 9 (0.2) 0.15
Renal impairment 418 (9.8) 371 (8.7) 0.07 65 (1.5) 54 (1.3) 0.30
Nasopharyngitis 405 (9.5) 383 (8.9) 0.39 1 (<0.1) 0 NA
Hypoglycemia 393 (9.2) 341 (8.0) 0.04 1 (<0.1) 3 (0.1) NA
Back pain 363 (8.5) 353 (8.2) 0.67 1 (<0.1) 2 (<0.1) NA
Dizziness 327 (7.7) 314 (7.3) 0.57 4 (0.1) 4 (0.1) NA
Urinary tract infection 326 (7.6) 288 (6.7) 0.10 4 (0.1) 2 (<0.1) NA
Anemia 316 (7.4) 307 (7.2) 0.68 0 0 —
Pain in extremity 302 (7.1) 317 (7.4) 0.56 1 (<0.1) 2 (<0.1) NA
Arthralgia 302 (7.1) 313 (7.3) 0.67 0 1 (<0.1) NA
Cough 265 (6.2) 283 (6.6) 0.45 1 (<0.1) 1 (<0.1) NA
Bronchitis 242 (5.7) 239 (5.6) 0.86 0 0 —
Dyspnea 223 (5.2) 213 (5.0) 0.60 6 (0.1) 5 (0.1) 0.76
Upper respiratory tract infection 223 (5.2) 229 (5.3) 0.80 1 (<0.1) 0 NA
Cataract 229 (5.4) 223 (5.2) 0.75 0 0 —
Constipation 203 (4.8) 241 (5.6) 0.07 0 1 (<0.1) NA
Headache 200 (4.7) 220 (5.1) 0.33 2 (<0.1) 4 (0.1) NA
* Events reported in 5% or more of either study group are shown. There were no predefined criteria for the adverse 
events listed. The investigators provided the reasons listed for the discontinuation of study drugs. Study groups were 
compared with the use of the chi-square test, where appropriate. Information on other relevant adverse events is avail-
able in the Supplementary Appendix. NA denotes not applicable.
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in the aliskiren group than in the placebo group, 
whereas overall glycemic control from baseline to 
the end of the study remained nearly identical 
between the two groups (data not shown). Diar-
rhea was a common adverse event but an infre-
quent cause of study-drug discontinuation.
At the interim analysis, there was an apparently 
higher risk of stroke in the aliskiren group than 
in the placebo group (hazard ratio, 1.34; 95% CI, 
1.01 to 1.77; nominal P = 0.044). With the subse-
quent orderly closeout of the study and the iden-
tification of an additional 392 patients with a 
primary event, including 72 patients with an 
adjudicated stroke, the overall neutral effect of 
aliskiren was confirmed, the effect size for stroke 
was reduced, and the nominal P value was no 
longer significant. (Table S9 in the Supplemen-
tary Appendix compares the rates of stroke in 
our trial with those in three other trials.) Addi-
tional adverse events are described in the Sup-
plementary Appendix.
Discussion
We found that the direct renin inhibitor aliskiren, 
when added to standard-of-care renin–angiotensin 
blockade in high-risk patients with type 2 diabetes, 
did not reduce cardiovascular or renal outcomes, 
as compared with placebo, and resulted in an 
increased number of adverse events. On average, 
blood pressure rose over the course of the trial in 
both groups, but slightly less with aliskiren (be-
tween-group differences, 1.3/0.6 mm Hg). How-
ever, no improvement in the primary composite 
outcome was observed, suggesting that factors 
such as hyperkalemia, renal dysfunction, and hy-
potension play a role in offsetting any beneficial 
effect of the treatment.17 When used individually, 
both ACE inhibitors and ARBs have been shown 
to reduce the incidence of major cardiovascular 
and renal events in patients with a variety of car-
diovascular disorders and those with nephropa-
thy.6,7,18-20 However, with the exception of two 
trials involving patients with chronic heart fail-
ure,21,22 the combination of these agents has not 
incrementally improved cardiovascular or renal 
outcomes as compared with monotherapy, and 
combination therapy has been associated with an 
increased incidence of hyperkalemia, hypoten-
sion, and renal dysfunction.9,10,23
Aliskiren inhibits the renin–angiotensin axis 
at the most proximal step, offering the theoreti-
cal advantage of preventing the compensatory rise 
in plasma renin activity, which has been associ-
ated with cardiovascular events.11,24 Aliskiren is 
an effective antihypertensive agent25 and, when 
added to either an ACE inhibitor or an ARB, has 
improved surrogate markers for clinical outcomes 
in some, but not all, studies. Specifically, aliski-
ren reduced urinary albumin excretion in patients 
with diabetic nephropathy14 and reduced plasma 
levels of B-type natriuretic peptides in patients 
with heart failure26 but did not improve left ven-
tricular remodeling in patients with acute myo-
cardial infarction.27
The results of the Aliskiren in the Evaluation of 
Proteinuria in Diabetes study, which compared 
aliskiren with placebo in patients with diabetic 
renal disease who were also receiving losartan 
therapy, are particularly pertinent here.14 The 
addition of aliskiren to the recommended dose 
of losartan resulted in an incremental 20% re-
duction in the urinary albumin-to-creatinine 
ratio. This improvement was greater than antici-
pated from the small reduction in systolic blood 
pressure (2 mm Hg). Data relating the degree of 
proteinuria or albuminuria to the risk of adverse 
cardiovascular events28 and renal events29 and 
analyses in clinical trials suggesting that the 
extent of pharmacologically produced reductions 
in proteinuria could be linked to improved out-
comes provided a rationale for our trial.30 The 
increased risks of hyperkalemia and hypotension 
with dual therapy with an ACE inhibitor and an 
ARB were known from prior studies.9,10,17,23
The recommendation by the independent data 
and safety monitoring committee for early termi-
nation of aliskiren was based on the members’ 
assessment that the excess risk of adverse events 
in the aliskiren group could not be offset by a 
reduction in major cardiovascular and renal 
events. At the time of the recommendation, with 
approximately 69% of the projected events, the 
point estimate for the primary composite out-
come (hazard ratio, 1.09; 95% CI, 0.97 to 1.22) 
favored placebo (single RAAS blockade). An in-
crease in the risk of stroke in the aliskiren group 
was apparent at the time of the interim analysis, 
but the nominal P value was no longer signifi-
cant at the closeout of the study. Three other 
major outcome trials comparing a different 
combination of renin–angiotensin system in-
hibitors (an ACE inhibitor plus an ARB) with 
monotherapy9,10,17,22,23,31 that were not restricted 
to patients with diabetes did not show an in-
creased incidence in stroke.
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The overall lack of benefit with regard to the 
primary composite cardiovascular and renal out-
come was observed across all the predefined sub-
groups. Although a serum potassium level higher 
than 5.0 mmol per liter was an exclusion criterion 
(with the measurement performed at a central 
laboratory 1 to 2 weeks before randomization), 
the results among patients with an elevated potas-
sium value at randomization raised a particular 
safety concern. Of those who underwent random-
ization with a serum potassium level higher than 
5 mmol per liter, the patients assigned to the 
aliskiren group were more likely to have at least 
one of the major cardiovascular or renal events 
reflected in the primary composite outcome than 
were those assigned to the placebo group.
Two trials in which aliskiren is being added to 
another renin–angiotensin system blocker in pa-
tients with heart failure are continuing under the 
supervision and at the recommendation of the data 
and safety monitoring committees of the tri-
als.32,33 However, the sponsor has discontinued 
a trial of aliskiren in elderly patients with mild 
hypertension, contrary to the recommendation 
from the data and safety monitoring committee.
A number of studies of various drugs have 
shown favorable changes in surrogate markers 
of disease progression, with subsequent studies of 
morbidity and mortality documenting a lack of 
clinical benefit or even harm.34,35 The present 
study documented more adverse events in the 
aliskiren group than in the placebo group without 
clinical benefits to offset them, which underscores 
the need to go beyond surrogate biomarkers and 
obtain risk–benefit data from clinical end-point 
trials to better inform clinical decisions.36
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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